

Campus Berlin-Buch: EPO GmbH announces strategic partnership with US company

EPO announces strategic cooperation with vivoPharm to strengthen access to the US Market



EXPERIMENTAL PHARMACOLOGY
& ONCOLOGY BERLIN-BUCH

Experimental Pharmacology & Oncology Berlin-Buch GmbH (EPO) has entered into a partnership with vivoPharm, an Australia/US-based preclinical pharmacological testing company, to introduce their Berlin-based collection of primary patient-derived tumor models more intensively to Cancer Research Institutions in the United States.



This new technology, for the first time offers US pharmaceutical and biotechnology companies the newest, most clinically-relevant models for validating drug candidates for cancer treatment and identification of biomarkers.

“With direct access to primary patient-derived tumors, US-based drug developers will have the clinically-most relevant method for validating cancer drug candidates. The combination of EPO’s primary patient-derived low passage tumors in concert with vivoPharm’s specialized and orthotopic models brings drug development to a new level.” said Dr. Jens Hoffmann, CEO of EPO.

EPO has been working with predictive primary patient derived tumor models for more than fifteen years.

The co-marketing agreement with vivoPharm adds another dimension to the organization’s service portfolio: clients can partner with EPO to characterize their own therapeutic compounds using not only models directly derived from patients, but also vivoPharm’s highly specialized orthotopic cancer models.

Both companies plans to actively promote primary patient-derived tumors at conferences and trade shows across the U.S., beginning with the American Association of Cancer Research’s Annual Meeting March 31.

About EPO (www.epo-berlin.com)

Experimental Pharmacology & Oncology Berlin-Buch GmbH (EPO) is one of Germany's leading contract research organization (CRO) that provides comprehensive services for preclinical oncology research world wide. EPO has specialized in development of tailored basic and translational research models to support drug development, starting from target validation and compound screening, and ending with integrational in vivo studies addressing pharmacology, pharmacokinetics, biomarkers, and tolerability. EPO's operations meet the high industrial standards, acknowledged by more than 125 customers worldwide. Our highly motivated and qualified team guarantees short response times, consistency of service, regular updates and transparency. EPO is based at the Campus Berlin-Buch, one of Germany's leading biotech location with 54 companies on-site.

Further information

Dr. Jens Hoffmann, CEO
Tel: +49 (0)30 94062876
Email: jens.hoffmann@epo-berlin.com

About vivoPharm (www.vivopharm.com.au)

vivoPharm is a leading contract research organization (CRO) that provides first class preclinical services in different disease areas in Europe, Australia and the United States. vivoPharm specializes in studies tailored to drug development, starting from compound libraries and ending with a comprehensive set of in vitro and in vivo data and reports, as needed for Investigational New Drug Applications (IND) filing. vivoPharm operations follow strict quality control methods and meet the highest industrial standards, acknowledged by our customers worldwide. Our highly motivated and qualified team guarantees short response times, consistency of service, regular updates and transparency. vivoPharm partners with MPI-Research, a leading CRP for toxicology and safety testing to extend its service portfolio.

Further information

Ralf Brandt, CEO and Managing Director
+61 439 433 425
ralf.brandt@vivopharm.com.au